Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugues de Lavallade

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Current Opinion in Hematology|January 19, 2021
Novel developments in chronic myeloid leukaemiaPatrick Harrington, Hugues de Lavallade
Drugs|September 10, 2011
Vaccination strategies in lymphomas and leukaemias: recent progressKatayoun Rezvani, Hugues de Lavallade
Expert Review of Hematology|January 19, 2020
What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?Patrick Harrington, Deepti Radia, Hugues de Lavallade
Expert Review of Hematology|November 4, 2024
What are the therapeutic options for previously treated myelofibrosis?Cassandre Petit, Hugues de Lavallade, Claire Harrison
Current Hematologic Malignancy Reports|April 14, 2017
The Role of Early Molecular Response in the Management of Chronic Phase CMLPatrick Harrington, Aytug Kizilors, Hugues de Lavallade
Annals of Hematology|April 8, 2022
High-flow nasal cannula oxygen in patients with haematological malignancy: a retrospective observational studySimon Tetlow, Rathai Anandanadesan, Leila Taheri, et al.
Haematologica|September 12, 2006
Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantationHugues de Lavallade, Mohamad Mohty, Catherine Faucher, et al.
Journal of the Intensive Care Society|November 8, 2019
The role of a critical care outreach service in the management of patients with haematological malignancyLeila Taheri, Rathai Anandanadesan, Hugues de Lavallade, et al.
Therapeutic Drug Monitoring|August 3, 2017
Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than MenSarah L Belsey, Robin Ireland, Kathryn Lang, et al.
The Lancet. Infectious Diseases|February 13, 2019
Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)Catherine Cordonnier, Sigrun Einarsdottir, Simone Cesaro, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Current Opinion in Hematology|January 19, 2021
Novel developments in chronic myeloid leukaemiaPatrick Harrington, Hugues de Lavallade
Drugs|September 10, 2011
Vaccination strategies in lymphomas and leukaemias: recent progressKatayoun Rezvani, Hugues de Lavallade
Expert Review of Hematology|January 19, 2020
What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?Patrick Harrington, Deepti Radia, Hugues de Lavallade
Expert Review of Hematology|November 4, 2024
What are the therapeutic options for previously treated myelofibrosis?Cassandre Petit, Hugues de Lavallade, Claire Harrison
Current Hematologic Malignancy Reports|April 14, 2017
The Role of Early Molecular Response in the Management of Chronic Phase CMLPatrick Harrington, Aytug Kizilors, Hugues de Lavallade
Annals of Hematology|April 8, 2022
High-flow nasal cannula oxygen in patients with haematological malignancy: a retrospective observational studySimon Tetlow, Rathai Anandanadesan, Leila Taheri, et al.
Haematologica|September 12, 2006
Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantationHugues de Lavallade, Mohamad Mohty, Catherine Faucher, et al.
Journal of the Intensive Care Society|November 8, 2019
The role of a critical care outreach service in the management of patients with haematological malignancyLeila Taheri, Rathai Anandanadesan, Hugues de Lavallade, et al.
Therapeutic Drug Monitoring|August 3, 2017
Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than MenSarah L Belsey, Robin Ireland, Kathryn Lang, et al.
The Lancet. Infectious Diseases|February 13, 2019
Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)Catherine Cordonnier, Sigrun Einarsdottir, Simone Cesaro, et al.
Pageof 6